Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

Blood (2023) 142 (Supplement 1): 7156.

https://doi.org/10.1182/blood-2023-190332

Published: 2023

Journal Articles

DNA Liquid Biopsies for Cancer-Associated Venous Thromboembolism Prediction

Blood (2023) 142 (Supplement 1): 569.

https://doi.org/10.1182/blood-2023-172820

Published: 2023

Journal Articles

The Complex Structural Variant Chromothripsis Can be Defined on Targeted Sequencing Panels, Allowing Direct Clinical Translation in Order to Improve Multiple Myeloma Prognostication

Blood (2023) 142 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2023-189316

Published: 2023

Journal Articles

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2023-187891

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Blood (2022) 140 (21): 2228–2247.

https://doi.org/10.1182/blood.2022015853

Published: 2022

Includes: Supplemental data

Journal Articles

Erythroid and Megakaryocytic Differentiation Program in JAK2 -Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm

Blood (2022) 140 (Supplement 1): 9160–9162.

https://doi.org/10.1182/blood-2022-169215

Published: 2022

Journal Articles

Validation of a Cell-Free DNA NGS Assay for Hematological Malignancies

Erika Gedvilaite, Sara DiNapoli, Coleman Spence, Monica S. Diosdado, Anna Razumova, Anita S. Bowman, Dana WY Tsui, Gilles Salles, Connie Lee Batlevi, Gottfried von Keudell, Ryan Ptashkin, Ahmet Zehir, Ryma Benayed, Michael F. Berger, A. Rose Brannon, Maria E. Arcila

Blood (2022) 140 (Supplement 1): 6430–6431.

https://doi.org/10.1182/blood-2022-167461

Published: 2022

Journal Articles

Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Blood (2022) 140 (Supplement 1): 9251–9253.

https://doi.org/10.1182/blood-2022-158783

Published: 2022

Journal Articles

Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 9228–9230.

https://doi.org/10.1182/blood-2022-163333

Published: 2022

Journal Articles

Clinical and Genomic Characterization of Secondary Acute Myeloid Leukemia with Mixed Phenotype

Pallavi Galera, Alexander Chan, Andriy Derkach, Ying Liu, Jeeyeon Baik, Christopher Famulare, Allison Sigler, Maria E. Arcila, Douglas A Mata, Ahmet Dogan, Martin S. Tallman, Ross L. Levine, Yanming Zhang, Mikhail Roshal, Jacob L Glass, Wenbin Xiao

Blood (2021) 138 (Supplement 1): 687.

https://doi.org/10.1182/blood-2021-151263

Published: 2021

Journal Articles

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

Blood (2021) 137 (10): 1377–1391.

https://doi.org/10.1182/blood.2020007897

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical Characteristics and Follow-up Post-Surgery of Women with Bia-ALCL Operated at a Single Institution

Paola Ghione, MD, Joshua Vorstenbosch, MD PhD FRCSC, Peter G. Cordeiro, MD, Maria E. Arcila, MD, Alison J. Moskowitz, MD, Colette Owens, MD, Natasha Galasso, BA, Jonas A. Nelson, MD, Ahmet Dogan, MD PhD, Colleen M. McCarthy, MD FRCSC, Steven M. Horwitz, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134393

Published: 2020

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Benjamin Diamond, MD, Neha Korde, MD, Alexander M. Lesokhin, MD, Eric L Smith, MDPhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X. Lu, MD PhD, Carlyn Tan, MD, Donna Massey, MSN, RN, Meghan Salcedo, BSN, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Kathryn Ciardiello, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata D Yellapantula, Francesco Maura, MD, Tim J Peterson, PharmD, Andriy Derkach, PhD, Sean Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan L. Shah, MDMS, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-140152

Published: 2020

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Hani Hassoun, MD, Carlyn Tan, MD, Urvi A Shah, MD, Sydney X. Lu, MD PhD, Benjamin Diamond, MD, Meghan Salcedo, RN, Kelly Werner, RN, Jenna Rispoli, RN, Julia Caple, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Isabel Concepcion, NP, Ciardello Amanda, MS, Aisara Chansakul, BS, Julia Schlossman, BA, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Angela Harrison, MS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata Yellapantula, PhD, Francesco Maura, MD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Andriy Derkach, PhD, Sergio A. Giralt, MD, Neha Korde, MD

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-142466

Published: 2020

Journal Articles

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-137552

Published: 2020

Journal Articles

Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism

Simon Mantha, MDMPH, Andrew Dunbar, MD, Kelly L. Bolton, MD PhD, Sean Devlin, PhD, Dmitriy Gorenshteyn, PhD, Mark Donoghue, PhD, Maria E. Arcila, MD, Gerald A. Soff, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-138579

Published: 2020

Journal Articles

Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase

Blood (2019) 134 (Supplement_1): 2148.

https://doi.org/10.1182/blood-2019-125068

Published: 2019

Journal Articles

Plasmacytoid Dendritic Cell Proportion Is Predictive of Risk and Outcomes in Myelodysplastic Syndromes

Alexander Chan, MD, Yanming Zhang, MD, Sean M. Devlin, PhD, Natasha Lewis, MD, Jeeyeon Baik, Maria E Arcila, MD, Virginia M. Klimek, MD, Mikhail Roshal, MD PhD, Wenbin Xiao, MD PhD

Blood (2019) 134 (Supplement_1): 5439.

https://doi.org/10.1182/blood-2019-122332

Published: 2019

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Donna Mastey, RN, Alexander M. Lesokhin, MD, Eric L Smith, MD PhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X Lu, MD PhD, Meghan Salcedo, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Ciardiello, BS, Elizabeth Tavitian, BS, Tala Shekarkhand, BS, Even Rustad, MD, Venkata Yellapantula, PhD, Francesco Maura, MD, Tim J Peterson, PharmD, Sean M. Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, PhD, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio Giralt, MD, Neha Korde, MD

Blood (2019) 134 (Supplement_1): 3127.

https://doi.org/10.1182/blood-2019-125842

Published: 2019

Journal Articles

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis

Zachary D. Epstein-Peterson, MD, Joseph Tripodi, Maria E Arcila, MD, Filiz Sen, MD, Vesna Najfeld, PhD, John Mascarenhas, MD, Ronald Hoffman, MD, Rajit K. Rampal, MD, PhD

Blood (2019) 134 (Supplement_1): 4173.

https://doi.org/10.1182/blood-2019-125379

Published: 2019

NARROW

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

DNA Liquid Biopsies for Cancer-Associated Venous Thromboembolism Prediction

The Complex Structural Variant Chromothripsis Can be Defined on Targeted Sequencing Panels, Allowing Direct Clinical Translation in Order to Improve Multiple Myeloma Prognostication

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Erythroid and Megakaryocytic Differentiation Program in JAK2 -Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm

Validation of a Cell-Free DNA NGS Assay for Hematological Malignancies

Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical and Genomic Characterization of Secondary Acute Myeloid Leukemia with Mixed Phenotype

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

Clinical Characteristics and Follow-up Post-Surgery of Women with Bia-ALCL Operated at a Single Institution

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism

Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase

Plasmacytoid Dendritic Cell Proportion Is Predictive of Risk and Outcomes in Myelodysplastic Syndromes

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only